Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights Get a risk prediction edge with lab data: Two characteristics vital to health underwriting accuracy

Get a risk prediction edge with lab data: Two characteristics vital to health underwriting accuracy

  • September 24, 2021
  • Posted in Underwriting

This post was last updated on September 29, 2021 at 10:43 am

Predicting risk in health insurance underwriting requires an accurate snapshot of a prospective group’s healthcare needs for the coming year. 

But for decades, lab data has been the missing factor when predicting group risk. 

Why is this an important factor?

According to the CDC, 70 percent of medical decisions depend on lab results.

What is the result?

Deeper clinical insights that allow you to rapidly deliver the most competitive bid with the lowest risk of loss.  

The status quo: Manual rate, prescription histories provide limited view

Current state: 

  • Many healthcare payers rely on manual rates based on past cost experience, using statistics and probability to predict the financial impact of an uncertain future state. 
  • Some payers have incorporated additional outside data (such as behavioral data and prescription histories) to add deeper insights to the underwriting process. 
  • Prescription histories provide valuable information on administered medications. This information can allow a payer to deduce the medical conditions impacting a group, but with limited confidence. 

The Problem: 

  • Traditional sources do not fully account for the current health of the group(s) to be quoted. 
  • Behavioral data does not always directly relate to the clinical health of prospective members.  
  • Prescription data may not provide insight into disease progression or severity, whereas laboratory data can. 
  • Medication histories are also based on prescription claims, that include a latency period (sometimes months) between when a therapy is prescribed and dispensed and when the claim is actually received and processed. Additionally, they provide little insight into an individual’s adherence to the guidance given to them by their care provider.

The Solution: Prognos Health Underwriting Risk Predictor uses lab data to deliver a comprehensive, timely clinical picture

Lab data is a largely untapped resource among health insurance underwriters, but it has two vital qualities necessary to provide the most accurate risk prediction scores possible.

  1. Clinical richness — Lab data provides a level of clinical detail that surpasses the limited medication and payment information available in a prescription history. With 70 percent of medical decisions depending on lab results, this dataset is the best indicator of disease severity and progression. 

    Results:
    • Lab data provides the earliest indicator of emerging conditions.
    • Payers no longer need to deduce diagnosis or disease severity. This specific information can be pulled directly from lab results, providing a clearer picture of member health.
    • Payers can more accurately predict risk with deeper clinical insights.
  1. Timeliness — Lab data is more timely than what’s available in actuarial sources or prescription histories. 

    Results:
    • Lab data provides payers with more up-to-date health information because it isn’t dependent on a claim being processed. It is accessible once a test is complete and the results are available.
    • By reducing latency, lab data helps eliminate gaps in care that might be present when relying on prescription or behavioral data alone. Lab data provides the best insight into current member health  — a must when predicting future healthcare usage.

So why isn’t lab data leveraged more? The main reason is, when purchased in bulk, lab data is not standardized and very difficult to operationalize in its raw form. 

Harness the power of lab data to improve your underwriting accuracy.

Prognos Health has spent years creating the gold standard of lab test results used by global leaders in the payer and pharmaceutical industries. Now, our data scientists have standardized and applied machine learning models to yield clinical insights that can be readily factored into an underwriting risk prediction score.

Prognos Underwriting Risk Predictor applies advanced analytics to its registry of more than 325M de-identified lives to predict the future cost of healthcare — a level of accuracy that can’t be matched by methods based on manual rate, prescription histories, or behavioral data.

See how this powerful tool can deliver measurable results to your underwriting efforts by receiving a custom proof of concept from one of our payer solution experts.

« Jumpstart Real World Data Platform Adoption For An Edge Over Life Science Competitors
Your 5-Point Checklist for Fueling Pharma Omnichannel Marketing With RWD »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.